Review: aspirin reduces vascular events but increases bleeding in primary and secondary prevention QUESTION In primary and secondary prevention, what are the benefits and risks of aspirin?
c Clinical Impact Ratings: GP/PF/Primary care 6/7; IM/Ambulatory care 6/7; Cardiology 6/7; Neurology 6/7
Aspirin v no aspirin (control) in primary and secondary prevention* 
COMMENTARY
A spirin, first synthesised in 1853 by Charles Frederic Gerhardt, a French chemist, has been widely recommended in recent years for the reduction of adverse CV events. Several studies and previous meta-analyses have suggested that aspirin has substantial benefit in the secondary prevention of CV events, 1 but the benefit-risk balance is less certain in primary prevention.
The review by Baigent et al validates previous observations that aspirin provides substantial net benefit in secondary prevention. Fewer CV events with aspirin exceed the bleeding hazards, irrespective of age or sex. For primary prevention, the benefits of fewer CV events and the bleeding hazards of aspirin appear to be of approximately similar magnitude. One clinically important subset of primary prevention patients is adults with diabetes and no known vascular disease, for whom aspirin is currently recommended, 2 but the evidence from this analysis does not support a net benefit. 2 large trials, A Study of Cardiovascular Events iN Diabetes (ASCEND) and the Aspirin and Simvastatin Combination for Cardiovascular Events Prevention Trials in Diabetes (ACCEPT-D), are currently recruiting patients with diabetes and no CV disease to ascertain the net benefit of aspirin for CV risk reduction. National organisations may have to reconsider recommendations on the use of aspirin in adults with diabetes so that investigators can enrol them in these important RCTs.
The meta-analysis by Berger et al investigated the effect of aspirin on CV events in a subset of patients with PAD and found no benefit. These findings contrast with the established role of aspirin in coronary artery disease and cerebrovascular disease. Limitations of the Berger analysis include low statistical power for showing clinically meaningful differences (20% between groups; older data, with most RCTs published before 1995; use of nonguideline recommended aspirin dosages, with only Continued on next page
Review: aspirin does not reduce CV events but may reduce non-fatal stroke in peripheral artery disease
QUESTION
In patients with peripheral artery disease (PAD), does aspirin reduce cardiovascular (CV) events?
REVIEW SCOPE
Included studies compared aspirin with placebo or control for reducing CV events in patients with PAD. Outcomes were a composite end point of non-fatal myocardial infarction (MI), non-fatal stroke, and CV mortality; individual components of the composite end point; all-cause mortality; and major bleeding. The meta-analysis had 88% power to detect a 25% reduction in the composite end point in the aspirin group.
REVIEW METHODS

Medline, EMBASE/Excerpta Medica, Cochrane Central
Register of Controlled Trials, Science Citation Index, Web of Science, Social Science Citation Index (1966-2008), reference lists, major scientific meetings, and supplemental index of the Antithrombotic Trialists' Collaboration were searched, and experts were contacted for randomised controlled trials (RCTs). 18 RCTs (n = 5269) met the selection criteria. 12 RCTs had Jadad scores of 2-5.
MAIN RESULTS
Meta-analysis showed that aspirin did not differ from placebo or control for the composite end point, non-fatal MI, CV mortality, all-cause mortality, or major bleeding (table) . A secondary analysis showed that aspirin reduced non-fatal stroke (table) .
CONCLUSION
Aspirin does not reduce cardiovascular events but may reduce non-fatal stroke in patients with peripheral artery disease.
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Aspirin v placebo or control for cardiovascular (CV) outcomes in peripheral artery disease* 
COMMENTARY
Continued from previous page 2 of 18 studies using currently recommended doses of 75-325 mg; and lack of individual patient data. These factors limit the clinical applicability of the results. Therefore, the results should not alter current recommendations for aspirin as an important drug for secondary prevention in patients with PAD. Additional high-quality, adequately powered RCTs are needed to provide more definitive data before changing patient care recommendations. Overall, the 2 reviews provide valuable insight into the role of aspirin in CV risk reduction. The Antithrombotic Trialists' collaboration analysis by Baigent and colleagues confirms the net benefit of aspirin in secondary prevention but raises questions about the value of aspirin in primary prevention, including patients with diabetes. Given the multiple limitations of the analysis in PAD patients, the data should not change current recommendations for use of low-dose aspirin and deprive patients of potential benefit. The only way to definitively answer the net incremental value of aspirin in these populations in the era of ubiquitous statin use will be through large, adequately powered RCTs.
